Ganitumab (AMG 479)

From - A Hematology Oncology Wiki
Jump to: navigation, search

in clinical trials

General information

Class/mechanism: Human monoclonal antibody that targets IGF-1R (insulin-like growth factor 1 receptor). IGF-1R plays a role in cell survival and cell cycle progression via the PI3K/Akt pathway. Ganitumab's mechanism of action may involve: 1. inhibition of binding of IGF-1 and IGF-2 to IGF-1R; 2. blocking the action of IGF-1R homodimers and IGF-1R/INSR (insulin receptor) hybrid receptors; 3. downregulating expession of IGF-1R.[1][2]
Route: IV
Extravasation: no information

For conciseness and simplicity, currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the package insert.

Patient drug information

No information available


  1. Amgen drug development pipeline
  2. AMG 479, a fully human anti–insulin-like growth factor receptor type I monoclonal antibody, inhibits the growth and survival of pancreatic carcinoma cells